Bifunctional PROTAC Compounds for CDK Protein Degradation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current CDK inhibitors face challenges with acquired drug resistance and limited efficacy in treating CDK-associated diseases, particularly in cancers where CDK4/6 inhibitors are not effective for all patients due to primary or secondary resistance.
Innovation Solution
Development of bifunctional proteolysis targeting chimera (Protac) compounds that bind specifically to CDK proteins and E3 ligases, promoting ubiquitination and degradation of target CDK proteins, thereby inhibiting their activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional CDK4/6 inhibitors are used to treat cancer, then initial therapeutic efficacy is achieved, but acquired drug resistance develops limiting long-term effectiveness
Solution Approach 1:
Instead of directly inhibiting CDK enzymatic activity, the invention uses PROTAC compounds that recruit E3 ubiquitin ligases to degrade CDK proteins through the ubiquitin-proteasome pathway. This inverted mechanism shifts from preventing enzyme function to eliminating the target protein itself, thereby overcoming resistance mechanisms that develop against traditional inhibitors.
Solution Approach 2:
The invention introduces E3 ubiquitin ligases as intermediary proteins that mediate the degradation of CDK targets. The bifunctional PROTAC compound acts as a bridge, with one end binding to the CDK target and the other end recruiting the E3 ligase, enabling targeted protein degradation through this intermediary mechanism.
2Productivity
If CDK enzymatic activity is inhibited directly, then cell cycle progression is blocked, but resistance mechanisms are activated reducing long-term effectiveness
Solution Approach 1:
The invention extracts the CDK target protein from the system through degradation, rather than merely inhibiting its function. By removing the protein entirely via ubiquitin-mediated proteolysis, the mechanism eliminates the target that resistance mechanisms would otherwise adapt to, maintaining sustained therapeutic pressure.
Solution Approach 2:
The invention changes the fundamental parameter from enzymatic activity inhibition to protein abundance reduction. By shifting from kinetic inhibition (affecting enzyme function) to thermodynamic removal (affecting protein concentration), the mechanism achieves more complete and sustained target suppression that resists adaptive resistance.
3Adaptability or versatility
If multiple CDK targets are inhibited simultaneously, then broader anti-proliferative effect is achieved, but off-target effects increase reducing safety profile
Solution Approach 1:
The invention segments the inhibition approach by using separate PROTAC compounds or modular designs that can selectively target specific CDK isoforms (CDK2, CDK4, CDK6) independently. This allows tailored combination therapies that achieve broad anti-proliferative effects while maintaining control over which specific targets are engaged, reducing uncontrolled off-target effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds offer a potential solution to overcome drug resistance by selectively degrading CDK proteins, potentially providing sustained therapeutic efficacy against CDK-associated diseases, including cancers, by targeting multiple CDKs and avoiding the need for direct enzymatic inhibition.
Implementation Method 1
A Protac can thus remove a target protein of interest by binding to the target protein and recruiting an E3 ligase thereto, which catalyzes ubiquitination and leads to subsequent degradation of the target protein.
Implementation Method 2
Such targeted protein degradation has emerged as a new paradigm to manipulate cellular proteostasis. In general, proteolysis targeting chimeras (Protacs) are bifunctional small molecules composed of two active domains and optionally a linker.
Data Source
AI summary
The disclosure relates to bifunctional CDK-modulating compounds having the structure W-L-T, where W is a targeting group that binds specifically to a CDK protein, T is an E3-ligase binding group, and L is absent or is a bivalent linking group that connects W and T together via a covalent linkage. Compounds and pharmaceutical compositions thereof can promote degradation of one or more CDK protein in a cell and are thus useful for treating, inhibiting, and preventing CDK-associated diseases, disorders and conditions, including cancers.